Physician profile
Mark Roy Kent
NPI 1700399839
$1,455.97
in general payments reported to CMS, 2019-2025
15 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $85.32 · 2022: $235 · 2023: $308 · 2024: $546 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,135.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $332.43 | 2021-2025 | Fasenra, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.20 | 2021-2025 | Jardiance |
| Abbott Laboratories | $195.09 | 2022-2025 | Proclaim, Freestyle Libre 3 |
| Lilly USA, LLC | $171.55 | 2021-2024 | Mounjaro, Jardiance |
| Boston Scientific Corporation | $101.93 | 2024-2025 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $86.55 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $82.95 | 2023-2024 | Spravato, Xarelto |
| Amgen INC. | $48.99 | 2024-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $33.55 | 2023-2024 | |
| Glaxosmithkline, LLC. | $29.62 | 2023 | Shingrix, Arexvy |
| Novo Nordisk INC | $16.52 | 2024 | Ozempic, Rybelsus |
| Inspire Medical Systems, INC. | $16.29 | 2024 | Inspire |
| Abbvie INC. | $16.20 | 2023 | |
| Exact Sciences Corporation | $15.55 | 2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $14.55 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.